 Meantime, a University of Georgia-based startup will launch a nasal COVID vaccine trial this fall. Sarah Lee Kessler has details. CyanVac LLC has received funding from Project NextGen, a federal initiative based in the U.S. Department of Health and Human Services. The new vaccine, well, that's based on a viral delivery platform.